Results 71 to 80 of about 6,098 (220)

Can We Learn to Heal Ourselves? The Promise, Perils, and Insights Behind Medicalizing Psychedelics [PDF]

, 2023
Before they were criminalized, psychedelics were once used in mental health research. Today, they are making a resurgence in the medical field following a long hiatus.
Seidel, Brielle
core   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Computational neurorehabilitation: modeling plasticity and learning to predict recovery [PDF]

, 2016
Despite progress in using computational approaches to inform medicine and neuroscience in the last 30 years, there have been few attempts to model the mechanisms underlying sensorimotor rehabilitation.
Burdet, E, Casadio, M, Krakauer, JW, Kwakkel, G, Lang, CE, Reinkensmeyer, DJ, Schweighofer, N, Swinnen, SP, Ward, NS   +8 more
core   +5 more sources

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Return of psychedelic medicine [PDF]

, 2012
Thesis (S.M. in Science Writing)--Massachusetts Institute of Technology, Dept. of Humanities, Graduate Program in Science Writing, 2012.Cataloged from PDF version of thesis.Includes bibliographical references (p.
Maurer, Lauren N. (Lauren Nichole)
core  

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

PSYCHEDELICS: CLINICAL EVIDENCE AND THERAPEUTIC MECHANISMS IN PSYCHIATRY [PDF]

Psychiatria Fennica
Interest and academic research on psychedelics and psychedelic-assisted therapy in the treatment of psychiatric disorders has increased dramatically in the past two decades. In many ways, psychedelics represent a new therapeutic paradigm in the context
JANI KAJANOJA, OSKARI KANTONEN, JUUSO KÄHÖNEN
doaj  

Modern Clinical Research on LSD [PDF]

, 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients.
A Garcia-Romeu, A Rickli, A Rickli, AB Wolbach Jr, AL Halberstadt, AL Halberstadt, Andrea E. Steuer, AV Lebedev, CM Hysek, CM Hysek, CS Grob, D Holland, D Marona-Lewicka, D Nutt, DB Terhune, DE Nichols, DE Nichols, DE Nichols, DV Sheehan, E Gouzoulis-Mayfrank, E Studerus, E Tagliazucchi, EA Schindler, F Hasler, F Mueller, FL Osorio, FX Vollenweider, FX Vollenweider, J Riba, J Seibert, J Speth, JC Bouso, JH Halpern, JJ Rucker, KA MacLean, KH Preller, KH Preller, KH Preller, KPC Kuypers, L Roseman, L Roseman, LD Simmler, LE Hollister, M Johnson, M Kaelen, M Kaelen, M Kometer, M Kometer, MA Geyer, Matthias E Liechti, ME Liechti, MJ Baggott, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Strajhar, Patrick C. Dolder, PC Dolder, PC Dolder, PC Dolder, PS Hendricks, R Kraehenmann, Rainer Kraehenmann, RE Belleville, RG Dos Santos, RJ Strassman, RJ Strassman, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RR Griffiths, RR Griffiths, S Ross, SD Muthukumaraswamy, T Passie, TS Krebs, TS Krebs, WE Fantegrossi, WN Pahnke, WN Pahnke, Y Schmid   +85 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Moral Neuroenhancement [PDF]

, 2017
In this chapter, we introduce the notion of “moral neuroenhancement,” offering a novel definition as well as spelling out three conditions under which we expect that such neuroenhancement would be most likely to be permissible (or ...
Douglas, Thomas, Earp, Brian D., Savulescu, Julian   +2 more
core